Abstracts

1013 – ART Reverses Negative Natural Selection of HIV Disease-Linked HLA-I in KwaZulu-Natal, South Africa

Background HLA is the most polymorphic region in the human genome, as the differential HLA-dependent impact of certain infections, inflammatory conditions, autoimmune diseases and cancers drive its evolution. However, clear examples of infection-driven evolution are rare. Here, we investigated antenatal cohorts in KwaZulu-Natal (KZN), South Africa, the region most severely affected by the global HIV…

958 – Genetics of Plasma Rifapentine Clearance During Pulmonary Tuberculosis Treatment in Study 31/A5349

Background Optimizing rifapentine (RPT) dosing is critical for improving tuberculosis (TB) treatment response. Study 31/A5349 (NCT02410772) compared two 4-month RPT-containing regimens — one with and one without moxifloxacin (MFX) — to the standard 6-month regimen. A key determinant of unfavorable TB outcomes in this trial was RPT exposure, with large interindividual variability. We hypothesized that…

985 – Genome-Wide Association With Postpartum Weight Change in Mothers on DTG or EFV in DolPHIN-2

Background DolPHIN-2 (NCT 03249181) randomised mothers initiating ART in late pregnancy to efavirenz (EFV)- or dolutegravir (DTG) based regimens. We previously reported no significant differences between arms in weight change post-delivery to 48w postpartum (PP), but observed heterogeneity with numerically greater weight gain in women from South Africa.  Here, we undertook a genome-wide association study…

969 – The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard

Background Tuberculosis preventive treatment (TPT) has been recognized by the World Health Organization as a critical intervention to eliminate tuberculosis. Rifampin TPT is critical to this goal, given high completion rates, short treatment lengths, and low side-effects. However, rifampin treatment has limitations by drug-drug interactions (DDI) with multiple medications   Methods A post-hoc data analysis…

971 – Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy

Background Tuberculosis preventive therapy (TPT) is a key intervention for tuberculosis (TB) elimination. The introduction of long acting (LA) TPT has the potential to enhance adherence, minimize treatment interruptions, improve completion rates, and extend protection against tuberculosis. Methods We conducted a cross-sectional in-person survey among patients in two high-burden TB countries to evaluate preferences, and concerns…

1012 – The Role of Maternal Broadly Neutralizing Antibody Activity in Perinatal Transmission of HIV-1

Background Despite increased availability to antiretroviral therapy, up to 5% of people living with HIV (PLH) still transmit HIV-1 to the infant. Broadly neutralizing antibodies (bNAbs) are the immunologic goal of HIV-1 vaccine candidates; however, in postnatal cohorts, we have reported the presence of bNAbs targeting a single epitope, which contributes to viral escape. We…

990 – Incidence of Tuberculosis in South African Women Living With HIV During Pregnancy and Postpartum

Background Tuberculosis (TB) causes considerable morbidity and mortality in pregnancy and postpartum, particularly in women living with HIV (WLH), but there are few data from cohorts of women on dolutegravir (DTG). In addition, while risk of active TB generally decreases with increasing body mass, there are few insights into this association during pregnancy and postpartum.…

976 – Pathway to Care Among Inpatients With Symptomatic Cryptococcal Meningitis in Johannesburg, SA

Background Cryptococcal antigen (CrAg) screening and pre-emptive treatment reduces risk of HIV-associated cryptococcal meningitis (CM) and death. Understanding the pathway to care following serum CrAg (sCrAg) screening is crucial for improving screening practices for people with advanced HIV disease. Methods We conducted structured interviews and collated hospital and laboratory data about patients with HIV-associated symptomatic…